16 results about "Catalpol" patented technology

This invention discloses a method for preparing Rehmannia glutinosa pulp with high retention of all its components after nine steaming and nine sun-drying processes, belonging to the technical field of deep processing of traditional Chinese medicine and preparation of functional foods. Using Rehmannia glutinosa processed through nine steaming and nine sun-drying processes from authentic Huai Rehmannia glutinosa as raw material, this method addresses industry pain points such as the inability to dry-crush candied Rehmannia glutinosa, low efficiency of traditional extraction methods, easy loss of heat-sensitive active ingredients, and difficulty in retaining all components. It adopts wet pulping instead of dry crushing and pioneers a three-stage progressive cell-wall breaking process of "enzymatic hydrolysis → ultrasound → microwave," achieving a synergistic effect of gentle biological cell-wall breaking, physically enhanced crushing, and low-temperature solubilization. Combined with vacuum low-temperature extraction, post-fermentation with probiotics, and low-temperature concentration, the entire process avoids membrane separation, protein removal, and purification of individual components. The finished product achieves a polysaccharide extraction rate of 90%–96%, a total retention rate of ≥65% for catalpol and rehmannia glycoside D, an increase of over 30% in melanoidin content, a decrease of over 25% in 5-HMF content, and an increase of over 13% in in vitro antioxidant activity. The process is gentle and controllable, suitable for large-scale industrial production.

This invention relates to the field of microbial fermentation technology, specifically a method for preparing Rehmannia glutinosa through simultaneous fermentation with compound bacteria and a laxative effect. This method involves extracting four types of probiotics that meet national safety standards: Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus casei, and Saccharomyces cerevisiae, and then formulating a high-concentration compound bacterial agent according to the live bacteria ratio. The initial fermentation material is adjusted to a material-to-water ratio of 1:5 and a suitable pH is maintained. After autoclaving, the materials are inoculated with bacteria at a weight-to-volume ratio for biological culture. The entire system is placed in a 37°C environment for continuous constant-temperature static co-fermentation. Through specific enzymatic hydrolysis and metabolic pathways of multidimensional bacterial communities, the absolute content of the core active ingredient catalpol and soluble dietary fiber in the final product is significantly increased. This bio-fermentation process effectively eliminates the potential risk of spleen and stomach irritation and damage from traditional Chinese medicinal materials. The resulting dry powder raw material can be widely and safely used in the preparation of microecological functional foods or pharmaceutical preparations targeting constipation symptoms caused by intestinal dryness and fluid deficiency.

This invention discloses the application of catalpol in the preparation of drugs for the prevention and treatment of schizophrenia and the alleviation of the glucose and lipid metabolism side effects of olanzapine. Using a schizophrenia model mouse model induced by the commonly used MK801, the therapeutic effect of catalpol on schizophrenia was investigated, and the therapeutic effect of catalpol on the glucose and lipid metabolism side effects of the commonly used drug olanzapine was investigated through long-term gavage administration. A systematic study of catalpol was conducted from pharmacodynamic, behavioral, and morphological perspectives. The results showed that catalpol effectively improved the behavioral characteristics of the schizophrenia model mice, alleviated negative symptoms and cognitive impairment; catalpol effectively improved olanzapine-induced obesity and lipid metabolism disorders. This provides a theoretical research basis for the development of catalpol into a drug for the treatment of schizophrenia.

This invention belongs to the field of biomedical technology and discloses the use of catalpol and mesenchymal stem cells in the preparation of drugs for treating liver fibrosis, wherein the concentration of catalpol is 50–200 μM and the concentration of exosomes is 20–50 μg / mL. Simultaneously, this invention constructs a spatially resolved liver fibrosis chip model based on GelMA hydrogel, integrating Kupffer-like cells, hepatic stellate cells, hepatic parenchymal cells, and endothelial cells through a layered sequential seeding strategy, achieving high-precision biomimicry of the liver fibrosis microenvironment. In vitro chip and in vivo animal experiments confirmed that this combined approach can significantly inhibit the expression of collagen synthesis-related genes, improve liver function indicators, and effectively reduce collagen deposition; its anti-fibrotic efficacy is significantly better than the simple superposition of the effects of single components, exhibiting a clear synergistic effect. This invention provides a novel synergistic drug strategy and a highly biomimetic in vitro evaluation platform for the treatment of liver fibrosis.

The invention provides a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of hypoglycemic products, and relates to the technical field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials: 4-8 parts of ginseng stem and leaf saponin, 8-16 parts of astragalus polysaccharide, 6-12 parts of astragaloside, 8-16 parts of catalpol, 6-12 parts of rehmannia D, 8-16 parts of verbascoside, 3-5 parts of raspberry polysaccharide, 4-8 parts of ellagic acid, 4-8 parts of pachymaran, 5-10 parts of pachymic acid, 8-16 parts of lycium barbarum polysaccharide, 40-62 parts of schisandra chinensis, 20-40 parts of Chinese yam, 40-62 parts of radix ophiopogonis, 40-62 parts of radix trichosanthis and 40-62 parts of rhizoma alismatis. The traditional Chinese medicine raw materials are pretreated by using the high-voltage pulsed electric field, and then ethanol extraction treatment is performed twice, so that the yield of the traditional Chinese medicine extract is high, and the traditional Chinese medicine composition obtained by mixing the traditional Chinese medicine extract with other active ingredients has an excellent effect of treating type II diabetes mellitus.

The invention discloses a method for detecting 10 components in rehmannia and processed products thereof, and belongs to the technical field of traditional Chinese medicine component detection. The invention particularly discloses a method for detecting catalpol, rehmannia D, mannose, fructose, glucose, cane sugar, melibiose, raffinose, manninotriose and stachyose in rehmannia and processed products by using a high performance liquid reversed phase chromatography. The elution gradient and flow velocity are 0-30 min, 30% A, 70% B and 0.3 mL / min; 30-40 min, 30% of A and 70% of B are adopted, and 0.4 mL / min is adopted; 40-60 min, 35% of A and 65% of B are adopted, and 1 mL / min is adopted; according to the detection method disclosed by the invention, the detection limit of catalpol and the detection limit of rehmannia D can be equivalent to the detection limit of a variable-wavelength ultraviolet-visible spectrophotometric detector; meanwhile, according to the detection method disclosed by the invention, each detection substance can meet quantitative requirements; and a foundation is laid for research on synchronous detection of various components in rehmannia, accurate control of medicinal material quality, clarification of a processing mechanism and guarantee of clinical curative effect.

The invention relates to a method for determining the content of effective components in a Kunxinning preparation. Comprising the following steps: step 1, preparing a reference substance solution, namely respectively taking a proper amount of one or two or more of catalpol, rehmannia glutinosa liboside D, paeoniflorin, calycosin-7-glucoside, (-)-syringinol-4-O-beta-D-furanselinosyl-(1-2)-beta-D-glucopyranoside, curculigoside, icariin and baohuoside I reference substances; preparing a reference substance solution; step 2, preparation of a test solution: taking a Kunxinning preparation, weighing the Kunxinning preparation, placing the Kunxinning preparation in a measuring flask, adding methanol to dilute the Kunxinning preparation to a scale, filtering the Kunxinning preparation, and taking a subsequent filtrate; step 3, a determination method: respectively and precisely sucking the reference substance solution and the test solution, injecting the solutions into a high performance liquid chromatograph, and determining component types and / or component contents; the chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as a filler, water is used as a mobile phase A, acetonitrile is used as a mobile phase B, gradient elution is performed, the flow velocity is 0.5-1.5 mL / min, the column temperature is 25-35 DEG C, the detection wavelength is 200-300 nm, and the sample size is 10-30 [mu] L.

The invention discloses an alveolar macrophage inhibitory natural product monomer and application thereof, and relates to the technical field of biological medicines. Seven natural product monomers including polyphyllin B, gentisic acid, catalpol, abscisic acid, aescin, ginsenoside and guaiacol are obtained through screening, and the menin / SETD2 interaction can be specifically inhibited. Experiments show that the monomers can inhibit expression of various inflammatory factors such as IL-1alpha, IL-1beta, IL-6 and the like induced by LPS in a dose-dependent manner; animal experiments prove that the monomers can obviously inhibit release of inflammatory factors induced by pathogens such as LPS and streptococcus pneumoniae, and can effectively relieve acute pneumonia and lung injury of mice. The provided natural product monomer is clear in target spot, specific in effect and broad in anti-inflammatory effect spectrum, and has important application prospects in treatment of cell / inflammatory factor storm related diseases caused by abnormal activation of alveolar macrophages.

This invention discloses a medicinal and edible herbal beverage for fundamental health restoration and its preparation process, belonging to the field of traditional Chinese medicine health beverage technology. The beverage is based on medicinal and edible ingredients such as ginger, poria cocos, platycodon grandiflorus, jujube seed, rehmannia glutinosa, ganoderma lucidum, polygonatum sibiricum, lily bulb, and jujube. It precisely combines active ingredients such as gingerol, hesperidin, platycodon saponin, jujube seed glycoside, catalpol, and total polysaccharides, achieving a balanced cooling and warming effect, and providing both nourishment and cleansing benefits. It can nourish yin and strengthen essence, calm the mind and invigorate the spleen, resolve stagnation and eliminate dampness, improving sub-health issues such as yin deficiency and essence depletion, spleen and stomach stagnation, and poor sleep. This invention employs a combined process of ultra-micro pulverization, compound enzymatic hydrolysis, anaerobic-microaerobic bidirectional microbial fermentation, low-temperature ultrasound-assisted extraction, and graded membrane purification and concentration, effectively improving the dissolution rate of active ingredients and the content of small molecule active substances. This solves the problems of low dissolution rate of active ingredients, easy inactivation of heat-sensitive substances, poor bioavailability, and difficulty in achieving efficacy in traditional processes.

The invention belongs to the technical field of medicines, and particularly relates to a composition for preventing and treating children obesity and a preparation method thereof. The composition comprises the following raw materials in parts by weight: 35-45 parts of active pharmaceutical ingredients and 8-15 parts of auxiliary materials, the active pharmaceutical ingredient is composed of sipunculus nudus polypeptide and catalpa glycoside in a mass ratio of 1: (1.5-3). The composition can inhibit the weight gain of mice with high fat diet, reduce the total cholesterol, triglyceride and low-density lipoprotein level in serum of the mice, and improve the high-density lipoprotein level in the serum. In addition, the composition can also improve liver fat accumulation and relieve fatty liver lesion caused by liver fat accumulation, and has no influence on renal functions.

The invention discloses a liquid chromatography-mass spectrometry detection method of bulbus fritillariae cirrhosae lung-heat-clearing syrup, which comprises the following steps: respectively taking a reference substance and the bulbus fritillariae cirrhosae lung-heat-clearing syrup, adding methanol for dissolving to obtain a reference substance solution and a test solution, and injecting the reference substance solution and the test solution into an HPLC-QQQ / MS liquid chromatography-mass spectrometer for detection. The detection method disclosed by the invention can be used for detecting rehmannia glutinosa-D, catalpol, amygdalin, platycodin-D, ophiopogonin-C and ophiopogonin-D in the fritillaria cirrhosa lung-heat-clearing syrup, is used for identifying active ingredients in the fritillaria cirrhosa lung-heat-clearing syrup, and perfects the quality control standard of the fritillaria cirrhosa lung-heat-clearing syrup. According to methodology verification, the detection method is high in accuracy and sensitivity, can realize specific detection of the characteristic components of the bulbus fritillariae cirrhosae lung-heat-clearing syrup, and has practical application value.

The application discloses application of glycoside compounds in prevention and treatment of plant pathogenic viruses and belongs to the technical field of pesticide antiviral agents.Taking a tobacco mosaic virus coat protein as an example, small molecules including sugar rings, such as Swertiamarin I (A0) and ZINC85593196 (B0), are screened through virtual screening, molecular dynamics simulation, molecular mechanics and MM / GBSA free energy calculation. Based on this, further optimization is carried out, and six compounds similar to the structure of A0, such as 4-methylumbelliferone-beta-D-xyloside (A1), gardenoside (A2), 4-methylumbelliferone-beta-D-pyranoside (A3), 4-methylumbelliferone-beta-D-pyranoglucoside (A4), catalpol (A5) and esculin (hemihydrate) (A6), are obtained, and in-vivo and in-vitro biological activity evaluation is carried out. The active ingredients screened by the above method have good inhibitory effect on plant viruses.

The invention discloses a traditional Chinese medicine composition for treating a neuronal intracellular inclusion body disease and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition provided by the invention is prepared from 11 medicinal materials including turtle shell, concha haliotidis, ruddle, nacre mother of pearl, semen cassiae, gastrodia elata, chrysanthemum morifolium ramat, prepared rehmannia root, Chinese yam, stiff silkworm and scutellaria baicalensis. The method adopts a step-by-step extraction and refining process and comprises the following steps: firstly, decocting mineral water with water; combining medicine residues with animal-derived traditional Chinese medicines, and carrying out ethanol reflux extraction; and finally decocting with the rest of plant-derived traditional Chinese medicines. After all extracting solutions are combined, active ingredients are enriched through macroporous resin gradient elution, finally, dry paste powder is obtained through concentration and spray drying, and capsules are prepared. The yield of the finished product dry paste is 22.7%, and the content of active ingredients needs to meet the quality control standard that baicalin is larger than or equal to 9.2 mg / g, gastrodin is larger than or equal to 3.5 mg / g, and catalpol is larger than or equal to 4.8 mg / g.

The invention discloses a flavor substance directional regulation and control enzymolysis method for a rehmannia and Chinese yam fermented beverage, which comprises the following steps: S1, gelatinizing rehmannia and Chinese yam at high temperature; s2, cooling the gelatinized slurry, putting the gelatinized slurry into an enzymolysis bin of fermentation equipment, adjusting the gelatinized slurry to be acidic, and adding beta-glucosidase for enzymolysis; s3, conveying the enzymolysis slurry to a fermentation bin of fermentation equipment, and then adding lactic acid bacteria for anaerobic fermentation; s4, after the acidity of the fermentation liquor is further reduced, saccharomycetes are added, and double-bacterium anaerobic fermentation is carried out at low temperature; and S5, after fermentation is completed, performing pasteurization, filtration and aging, and then performing filling. The beta-glucosidase is used for performing directional enzymolysis on iridoid glycoside flavor substances such as catalpol and the like, the problem that the fermented beverage has bitter taste is solved, double-bacterium combined aeration is subsequently used for fermentation, breeding of infectious microbes is inhibited, and the taste of the beverage is enriched by generated various lipid substances.

The invention relates to a traditional Chinese medicine component compound. The traditional Chinese medicine component compound comprises baicalin, salidroside and catalpol. The traditional Chinese medicine component compound disclosed by the invention is a traditional Chinese medicine compound, pays attention to enhancement of an autoimmune system, and is free of toxic and side effects and reasonable in formula; the traditional Chinese medicine composition effectively aims at main pathogenesis of ischemic encephaledema and cerebral ischemia, such as reduction of cerebral moisture content, reduction of cerebral ischemia area, alleviation of neurological dysfunction, reduction of neuronal apoptosis and the like, and has a remarkable curative effect; the raw materials are wide in source and easy to obtain, can be extracted and biosynthesized by adopting crude drugs, can also be directly used as chemical synthesis products, and are convenient for preparation and large-scale production.

The invention belongs to the technical field of blood-glucose-reducing fine dried noodles, and particularly relates to blood-glucose-reducing fine dried noodles containing radix astragali, folium mori and radix rehmanniae extracts and a pressing process, dried radix astragali is taken to be sliced, 8-12 times of deionized water is added, reflux extraction is performed twice with hot water at the temperature of 80-85 DEG C, each time of reflux extraction is performed for 1.2-1.8 hours, filtrate is combined, the filtrate is subjected to reduced pressure concentration under the conditions that the temperature is 60 DEG C and the vacuum degree is-0.08 MPa to obtain extract with the relative density of 1.10-1.15, and the dried radix astragali is prepared into the blood-glucose-reducing fine dried noodles. The preparation method comprises the following steps: preparing a powder extract containing more than or equal to 0.2% of astragaloside, carrying out spray drying at an air inlet temperature of 170-190 DEG C and an air outlet temperature of 75-85 DEG C to obtain a powder extract containing more than or equal to 0.2% of astragaloside, crushing dried mulberry leaves, adding 7-9 times of deionized water, carrying out constant temperature extraction twice at 70-75 DEG C for 0.8-1.2 hours each time, combining filtrates, and carrying out treatment according to concentration and drying conditions in the step 1 to obtain a powder extract containing more than or equal to 0.1% of 1-deoxynojirimycin. The preparation method comprises the following steps: slicing radix rehmanniae recen, adding 8-10 times of deionized water, performing reflux extraction twice at 75-80 DEG C for 1.0-1.5 hours each time, and combining filtrates; and performing treatment under the conditions of concentration and drying in the step 1 to obtain a powdery extract with catalpol content of more than or equal to 0.1%.